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Shared decision-making: Personal, professional and politicalGood communication is key to satisfactory and satisfying
medical consultations and encounters of all kinds, be they in the
GP surgery; in a hospital setting; in public health promotions;
and in public health programmes such as screening or vaccination.
Jane Smith’s editorial in the BMJ of 6th November 2010was enti-
tled ‘Decisions, decisions.’.1 It was subtitled “If choice can be
disabling as well as enabling, it’s important that “choice” in the
serious matter of healthcare is well managed and supported.” Her
editorial gave tasters for various papers in that issue on topics
around choice and decision-making, set against the background of
the UK government’s desire to increase patient choice. Angela Coul-
ter’s view is that use of evidence-based decision aids improves
patients’ knowledge, understanding of options, and perception of
risks and can reducedemand for surgical procedures.2 But clinicians’
unwillingness to offer such supportwas identiﬁed as a barrier to uti-
lising such support. Glyn Elwyn and colleagues worried that much
more research has gone into creating decisions aids themselves
than into creating a culture where professionals espouse shared
decision-making as a skill and routinely used the tools.3 What is
the use of developing expertise in decision aids; communication of
‘numbers’; of risk; etc., if clinicians don’t fully realise how important
these ancillary skills are when in consultation with their patients?‘Informed uptake’ or ‘informed decision-making’?21
A further paper was a report of an Australian randomised study
by Sian Smith and colleagues who had compared the effects of
using one of two variants of a decision support aid in a group of
people with a low level of education and literacy with a similar
group of people who had received only standard information about
screening for bowel cancer (by faecal occult blood testing). They
found that the people using the decision aidmade amore satisfying
decision: the authors report that they showed greater knowledge,
made a more informed choice, and had less decisional conﬂict
that the people who didn’t. But fewer of them decided to take the
test. This fact evidently caused some concern to Hilary Bekker
who provided the editorial comment on these and other screening
papers.4 She suggested that in the context of bowel cancer
screening the facts might be better structured to facilitate adher-
ence with testing – “a policy of informed uptake rather than
informed decision-making”. This drew a number of rapid responses
from people concerned by this desire to manipulate the presenta-
tion of the facts and her preference for ignoring the ethical aspects
of offering screening to healthy people. This failure is perhaps best
expressed in Craig B. Dalton’s rapid response to her paper: “This1743-9191/$ – see front matter  2010 Surgical Associates Ltd. Published by Elsevier Lt
doi:10.1016/j.ijsu.2010.11.013editorial is amoral. Neither immoral nor moral, but writtenwithout
any moral sensibility – in an ethics-free zone.”
Jane Smith concluded her editorial by drawing attention to
a letter published in that same issue, written by Michael Baum
and colleagues, signed a group of people concerned at the failure
of the NHS breast screening programme to provide women with
themeans of making a proper decision regarding screening, in spite
of repeated calls for them to do so.5 She wondered if the many
authors of that letter would agree with Bekker’s suggestion. I, for
one, as a layperson diagnosed with a screen-detected carcinoma
in 1991, campaigning for “genuinely ‘informed consent’ ” in
research and healthcare since then, certainly do not agree.6A historical case study: informed consent for breast screening
by mammography
Should anyone be in doubt about whether a policy of informed
uptake rather than informed decision-making should be adopted, it
is hoped that the following history of numerous attempts to see
that women invited for breast screening by mammography are
properly informed may provide food for thought and help your
decision-making.
Themethods used for inviting women in the UK for two decades
to attend for population breast screening by mammography by the
NHS Breast Screening Programme (NHS BSP) have been openly,
repeatedly and increasingly challenged. It and resultant trials
seeking evidence for management of screen-detected abnormali-
ties have been challenged on both ethical and practical grounds
for many years. The last couple of years in particular have seen
compelling evidence of many kinds, and include several systematic
reviews with covering editorials in leading journals.7–10 Professor
Klim McPherson’s recent review,11 called for by the BMJ, drew
similar conclusions to other reviews that “there is no doubt that
screening for breast cancer has limited beneﬁt and some possibility
of harm for an individual woman and marginal cost effectiveness
for a community.”
Yet women are still being invited today by the NHS BSP to be
screened without beneﬁt of proper information in spite of repeated
challenges over 2 decades about the inadequacy of their consent
process and available models of better quality information.12,13
Respect for a woman’s autonomy and her decision-making ability –
if given true evidence-based facts about the potential for breast
screening by mammography to be of beneﬁt to her, as well as its
potential to cause her harm – has been behind the motivation for
these challenges. As respect for autonomy is one of the four ethicald. All rights reserved.
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proper medical professional behaviour, the effect on the uptake to
the programme should not be a consideration, particularly since
there are no herd immunity factors to consider within the range of
disease that is labelled as ‘breast cancer’. Conversely, the conse-
quences of being diagnosed through the programme with
a pseudo-, non-invasive ‘carcinoma’ can result in repercussions on
the next generation as my daughter and I have personally
experienced.14
Fiona Godlee in her covering editorial15 described the “sense of
measured outrage” that such an important national programme
could exist for so long with so many unanswered questions”, and
drew attention to McPherson’s call for a “full and dispassionate
examination of individual patient data from all recent studies
and, in the meantime, much more honesty from the NHS screening
programme about the scientiﬁc uncertainties.”
An alternative proposal: risk assessment/risk management
(RARM)
Proposals were put before the House of Commons Science and
Technology Committee some while ago by Michael Baum for
a ‘risk assessment/risk management’ (RARM) scheme, offered as
a transitional replacement for the current breast screening pro-
gramme.16 It would, by triage, sort women who came forward
into low, medium and high-risk of getting breast cancer. Software
is available to do this, already in use in clinics in the United States.
Women identiﬁed as at low risk would not require to be screened,
but could be given lifestyle advice (re: smoking; consumption of
alcohol, obesity; diet; exercise) which would also lower their risk
of a much more likely threat, that of cardio-vascular disease. The
high-risk women would receive genetic and other counselling.
The medium risk women (who might just beneﬁt from being
screened) who wanted to consider whether to go forward for
screening, would be properly informed about the known harms,
limitations and consequences of going forward to be screened by
mammogram, as well as the small chance of beneﬁt, based on the
most up-to-date evidence. Her decision would be made with the
help of equally well-informed health professionals who had been
trained to communicate the ‘numbers’ (statistics) properly and
well.17,18 The pros and cons - the risk of potential harm when set
against the potential for possibility of beneﬁt - tailored to her
own individual risk proﬁle (age; family history; lifestyle factors
(as listed above) etc.) - would be discussed with her with the
help of decision tools. This method would at least begin to reduce
the number of women going unnecessarily (unknowingly) to be
incorrectly labelled with ‘cancer’, and may also begin to lower the
level of fear in women whipped up by current approaches.
A call for individual patient data for analysis and appraisal by
NICE
As called for byMcPherson and Godlee, the National Institute for
Health and Clinical Excellence (NICE) should call for individual
patient data from screening trials to be made available for indepen-
dent analysis. An independent organisation such as the Clinical
Trials Service Unit (CTSU) could be commissioned by NICE to do
this.
Ethical considerations
The ethical considerations, sometimes brushed aside as being of
secondary importance, must be emphasised. As citizens paying the
costs for this activity, and targets for numerous screening invita-
tions and programmes, should we not all be more concerned andask ourselves whether the ethical imperatives to put a stop to
duping women with ‘The Facts’19; whether harming more women
than are being helped; whether failing to respect individual
women’s dignity and autonomy are more than sufﬁcient reasons
to insist on proper informed consent, and, in the case of breast
cancer, warrant an instant move towards a RARM initiative? This
method would utilise expertise and resources to better effect and,
moreover, would satisfy the current need to cut unnecessary waste
in health expenditure. Risk management for prostate cancer is the
preferred and well-accepted approach – why not for breast cancer,
and other diseases as appropriate?
When considering the ‘rightness’ of this approach against the
prevarications; iniquitous delays; failure to tell the truth; failure
to justify ‘estimates’ of 1400 lives saved by screening per annum
of the NHS BSP; etc., should we not also ask ourselves where our
energies, time and money should best be used, to put a stop to
the current process of ‘trawling a healthy population group’ which
is continuing to damage millions of women psychologically, physi-
cally, socially? Is it not well past time to put a stop to the current
paternalistic system of coercing women to come forward, since
many hold that it is morally unacceptable and a disrespectful way
to treat competent adults capable of making their own decisions
if given evidence-based information; decision tools; ‘numbers’
presented graphically as well as in tables and words to aid an
individual’s risk assessment; and ‘neutral’ advice from competent
health professionals?
Furthermore, (leaving side the different parameters that obtain
for making policy decisions about offering population screening in
different disease areas,) a morally correct motivation for providing
‘The Facts’ when offering breast screening should surely also be the
motivation for offering ‘the facts’ in other population screening
programmes, including that for bowel cancer?
Action taken; further recommendations for action
The Cancer Director and the NHS BSP were speciﬁcally chal-
lenged 21 months ago,20 because there had been no action in
response to numerous other previous calls to reform the breast-
screening programme. Since that February 2009 challenge, well
over 3 millionwomen in the UK will have gone through the current
inadequate screening system. Good quality evidence has been accu-
mulating in that time to reduce the uncertainty about the harm/
beneﬁt ratio. McPherson and Godlee and numerous others have
called for an independent analysis using individual patient data.
Concrete proposals have been put before the Science and Tech-
nology Committee for an alternative RARM approach. Women
continue to be unknowingly over-diagnosed and over-treated. Citi-
zens are waiting for an explanation and a constructive response
from those NHS ofﬁcials responsible for proﬂigate use of public
money. How much longer do we have to wait? What other action
can be taken? Perhaps citizens in our democracy who are now all
targets for being persuaded to attend for screening of one kind or
another, should ask their own spokesperson – their member of
parliament – to see that equity, respect for autonomy, justice,
beneﬁcence, and non-maleﬁcence govern how healthy people are
approached and treated in such public health programmes?
Setting this account against an academic’s suggestion for a policy
of informed uptake rather than informed decision-making, it is
clear that much needs to be done to see that citizens are enabled
to make well-informed decisions, and that doctors, surgeons, clini-
cians of all kinds, need to be aware, not just of the evidence, the
practicalities and technicalities of offering screening programmes,
but also of the ethics that should underpin personal, professional
and political decision-making. We all have a responsibility,
whether health professional or layperson, to be vigilant with
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None declared.References
1. Smith J. Decisions, decisions.. BMJ 2010;341:c6236.
2. Coulter A. Do patients want a choice and does it work? BMJ 2010;341:c4989.
3. Elwyn G, Laitner S, Coulter A, Walker E, Watson P, Thomson R. Implementing
shared decision making in the NHS. BMJ 2010;341:c5146.
4. Bekker H. Decision aids and uptake of screening. BMJ 2010;341:c5407.
5. Baum M, Thornton H, Goetzsche P, Bewley S, Jorgensen KJ, Barratt A, et al. Still
awaiting screening facts. BMJ 2010;341:c6152.
6. Thornton HM. Breast cancer trials: a patient’s viewpoint. Lancet 1992;339:44–5.
7. Kalager M, Zelen M, Langmark F, Adami HO. Effect of screening mammography
on breast-cancer mortality in Norway. N Engl J Med 2010;363:1203–10.
8. Welch HG. Screening mammography – a long run for a short slide? N Engl J Med
2010;363:13.
9. JørgensenKJ, Zahl PH,Gøtzsche PC. Breast cancermortality inorganisedmammog-
raphy screening in Denmark. A comparative study. BMJ 2010;340:c1241.
10. Jørgensen KJ, Gøtzsche PC. Who evaluates public health programmes? A review
of the NHS Breast Screening Programme. J R Soc Med 2010;103:14–20.
11. MacphersonK. Shouldwescreen forbreast cancer?BMJ2010 (24 June);340:c3106.
12. Goetzsche P,HartlingOJ, NielsenM, Brodersen J. Screening for breast cancerwith
mammography. Leaﬂet available at: www.screening.dkandwww.cochrane.dk;
January 2008.
13. Sense about Science.Making Sense of Screening. 2009.www.senseaboutscience.
org.uk/PDF/MSOScreening.pdf.14. Thornton H. Pairing accountability with responsibility – the consequences of
screening ‘promotion’. Med Sci Monit 2001;7(3):531–3.
15. Godlee F. Breast screening and other ﬁghts. BMJ 2010;341:c4096.
16. Baum M. Should routine screening by mammography be replaced by a more
selective service of risk assessment/risk management? Womens Health January
2010;6(1):71–6.
17. Evans I, Thornton H. Transparency in numbers. The dangers of statistical illit-
eracy. J R Soc Med 2009;102(9):354–6. doi:10.1258/jrsm.2009.090214.
18. Thornton H. Statistical illiteracy is damaging our health. Doctors and patients
need to understand numbers if meaningful dialogues are to occur. Int J Surg
2009;7:279–84.
19. NHSBreast Screening Programme. The facts. Revised 2009,www.cancerscreening.
nhs.uk/breastscreen/./ia-02.html; 2006.
20. Baum M, McCartney M, Thornton H, Bewley S, Pharoah P, Kaplan RM, et al. Breast
cancer screening peril. Negative consequences of the breast screening programme.
The Times, http://www.timesonline.co.uk/tol/comment/letters/article5761650.ece?
print¼yes&randnum7; 19th February 2009.
21. Smith SK, Trevena L, Simpson JM, Barratt A, Nutbeam D, McCaffery KJ. A deci-
sion aid to support informed choices about bowel cancer screening among
adults with low education: randomised controlled trial. BMJ 2010;341:c5370.
doi:10.1136/bmj.c5370.
Hazel Thornton*
Department of Health Sciences, University of Leicester, UK
*Correspondingauthor. “Saionara”, 31 Regent Street, Rowhedge,
Colchester CO5 7EA, UK. Tel.: þ44 0 1206 728178;
fax: þ44 0 1206 728911.
E-mail address: hazelcagct@keme.co.uk
Available online 1 December 2010
